Dexrazoxane in Veterinary Oncology: Anthracycline Rescue and Cardioprotection

dexrazoxane is covered as emergency extravasation antidote and selected anthracycline cardioprotectant, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Emergency extravasation antidote and selected anthracycline cardioprotectant. Dexrazoxane.

Dexrazoxane.

Dexrazoxane chelates iron and reduces anthracycline-associated free-radical injury; topoisomerase-II interactions also contribute to tissue and cardiac protection.

AAHA identifies dexrazoxane as an option for doxorubicin extravasation and discusses cardioprotection. Extravasation is an oncologic emergency, and this page is not a home first-aid protocol.

AAHA identifies dexrazoxane as an option for doxorubicin extravasation and discusses cardioprotection. Extravasation is an oncologic emergency, and this page is not a home first-aid protocol.

Urgent intravenous treatment in a chemotherapy-capable clinic

Veterinary evidence for extravasation includes a small canine case series, while much of the supporting evidence comes from human studies and experimental work. Timing appears important, but no owner should use a website to reproduce an emergency protocol.

Dexrazoxane itself requires prescription, intravenous access and monitoring. Treatment decisions may affect chemotherapy exposure and need coordination with wound, cardiac and oncology teams.

Topical dimethyl sulfoxide and dexrazoxane should not be combined casually; AAHA notes evidence that concomitant use may reduce dexrazoxane efficacy in experimental models.

This audit did not identify an FDA-approved canine or feline dexrazoxane oncology label. Veterinary use is extra-label and specialist-directed.

Multi-region specialist use; approval and supply vary.

Stop the infusion and activate the clinic extravasation protocol immediately if leakage is suspected. The team documents drug, estimated exposure, site findings and time, then follows tissue, pain, perfusion and systemic status. Cardiac-protection use requires a separate cumulative-risk assessment.